Loading
GARNET showed that the PD-1 antibody dostarlimab produced lasting responses in about four in ten women with mismatch repair-deficient endometrial cancer that had returned after chemotherapy, which won the drug its first approvals.
GARNET was a large phase 1 dose-finding and expansion study of dostarlimab, a PD-1 antibody, in advanced solid tumours. Its expansion cohorts enrolled recurrent or advanced endometrial cancer after platinum, split by mismatch repair status, and a cohort of non-endometrial mismatch repair-deficient tumours. The primary endpoints for the expansion cohorts were objective response rate and duration of response by independent review.
In the mismatch repair-deficient endometrial cohort roughly four in ten patients responded and most responses were durable, with a lower response rate in the proficient cohort. Dostarlimab received accelerated approval in the United States in April 2021 for mismatch repair-deficient recurrent endometrial cancer and later a tumour-agnostic approval for mismatch repair-deficient solid tumours; the RUBY trial then moved it into first line with chemotherapy.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
729 enrolled.
95% CI 30.6 to 54.6; median follow-up 11.2 months
SourceShares GSK and the tag subtype-trials.
Shares Endometrial cancer and the tag subtype-trials.
Shares Immune checkpoint inhibitors and the tag subtype-trials.
Shares Immune checkpoint inhibitors and the tag subtype-trials.
Shares Immune checkpoint inhibitors and the tag subtype-trials.
Shares Immune checkpoint inhibitors and the tag subtype-trials.
Shares Immune checkpoint inhibitors and the tag subtype-trials.
Shares Immune checkpoint inhibitors and the tag subtype-trials.